Skip to main content

Advertisement

Table 3 Immunoreactivity of KGHR1-scFv antibody in human tumour tissues and cell lines

From: A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues

Immunoreactivity (HSCOREsa) Immunocytochemistry
Tumour tissues Cases Primary tumour tissues Normal tissues Tumour cell lines Results
Colorectal cancer 30 180.54 ± 79.21 7.31 ± 2.13 BGC853 +
Gastric cancer 25 150.17 ± 64.31 7.13 ± 1.99 MKN28 +
Oesophageal cancer 25 151.42 ± 59.13 8.21 ± 2.38 HCT116 +
Bladder cancer 25 149.37 ± 79.27 7.23 ± 2.15 QGY7703 +
Lung adenocarcinoma 20 199.45 ± 69.11 8.13 ± 2.17 SMMC-7721 +
Lung squamous cell carcinoma 20 185.37 ± 71.64 7.53 ± 2.23 HepG2 +
Lung small cell carcinoma 19 146.25 ± 83.00 7.78 ± 2.17 MDA-MB-231 +
Papillary thyroid carcinoma 20 191.67 ± 82.71 7.93 ± 2.76 MDA-MB-435 +
Hepatocarcinoma 22 168.25 ± 79.33 8.47 ± 3.18 MCF7 +
Prostate carcinoma 25 145.37 ± 75.35 8.52 ± 3.43 HeLa +
Breast cancer 24 165.73 ± 63.28 7.93 ± 2.56 SKOV3 +
Endometrial cancer 30 153.32 ± 57.00 8.73 ± 3.63 Hep2 +
Glioma 20 131.50 ± 42.59 10.28 ± 5.00 T24 +
Renal cell carcinoma 24 89.61 ± 53.73 11.27 ± 4.91   
  1. aMean ± SD